

FOR IMMEDIATE RELEASE

For More Information:

Tom Trotter, CEO
Angioscore, Inc.
510-263-0480 x.114

Lisa Suennen, Managing Director
Psilos Group
415-945-7010 x.11

AngioScore Names Medical Device Industry Veteran Thomas R. Trotter Chief Executive Officer

ALAMEDA, CA – August 9, 2005 – AngioScore, Inc.'s Board of Directors announced today that Thomas R. Trotter has been appointed Chief Executive Officer effective immediately. Mr. Trotter succeeds Ephraim Heller, founder, current Chairman and Chief Executive Officer, who will be retiring from the Company.

Mr. Trotter brings to AngioScore more than 28 years of experience in the medical device industry. Most recently he served as President and Chief Executive Officer of Orthologic, Inc., a publicly traded orthopedics company. In his tenure from 1997 to 2005, Mr. Trotter led the transformation of OrthoLogic from an entrepreneurial venture into a professionally managed public company. He subsequently led the successful divestiture of the Company's device businesses and the acquisition of drug technology which transformed OrthoLogic into a late stage biotech company.

Prior to Orthologic, Mr. Trotter worked for Mallinckrodt, Inc. as President, Critical Care Division and U.S. Markets, where he was responsible for \$400 million in worldwide sales and 2,500 employees. He joined Mallinckrodt via the acquisition of Diamond Sensor Systems, a venture backed medical device company in the blood chemistry analysis business, where he served as President and Chief Executive Officer. Previously, Mr. Trotter worked for Shiley, Inc, then a division of Pfizer, where he managed the worldwide Cardiopulmonary Division.

Mr. Trotter holds an M.B.A from Pepperdine University and a Bachelor of Science degree in business administration from the University of Maryland. He will be relocating from Arizona to the company's headquarters in the Bay Area.

"We are delighted to be able to attract someone of Tom's caliber and experience to AngioScore and are confident in his ability to shepherd the Company while it moves toward commercialization of its products and expands to meet an incredibly rich market opportunity," commented Lisa Suennen, a member of AngioScore's Board of Directors and Managing Director of Psilos Group, a private equity firm that co-led the Company's last round of investment. "The Board and management team are excited to enter this next phase of the Company's development under Tom's leadership."

"I am very excited to be joining AngioScore", commented Mr. Trotter.. "The company has developed outstanding catheter based technology from which we expect to introduce a whole series of next generation products for the worldwide Interventional marketplace. The company

has made tremendous progress to date, due to the hard work and dedication of a very skilled and talented employee group, and I look forward to becoming a contributor to the company's future success. "

Mr. Trotter joins AngioScore as it seeks approval from the U.S. Food and Drug Administration for its AngioSculpt line of innovative coronary and peripheral scoring balloon angioplasty catheters. The Company has begun marketing its products in Europe after receiving its C.E. Mark for both the coronary and peripheral applications.

Ms Suennen added, "Ephraim Heller has been instrumental in establishing the company's strategic vision, financing and product distribution efforts since its founding in 2003. He has been an essential part of the success the Company has achieved to date and the Board and his colleagues sincerely appreciate all that he has contributed. His presence will be greatly missed and we wish him tremendous success with his future endeavors". Mr. Heller stated, "I am grateful to have worked with such a talented group of partners and employees during the startup, R&D and clinical trial phases of AngioScore's development, and I am delighted that Tom will lead the company as it proceeds toward worldwide commercialization of the AngioSculpt product line."

About AngioScore

AngioScore, Inc. (www.angioscore.com) is an endovascular therapy company located in Alameda, California. The company's first product is the AngioSculpt Scoring Balloon Catheter. AngioSculpt is an investigational device in the United States. AngioScore can be contacted at +1-510-263-0480 or info@angioscore.com.

(###)